Improvement of Intravenous Immunoglobulin Therapy for Bullous Pemphigoid by Adding Immunosuppressive Agents

Intravenous immunoglobulin for treatment of severe acquired bullous epidermolysis refractory to conventional immunosuppressive therapy.

Acquired bullous epidermolysis is a chronic and rare bullous subepidermal disease. It usually begins in adulthood and its etiology is unknown although it is associated with antibodies against type VII collagen. There are spontaneous and trauma induced formation of blisters that may cause serious complications. Treatment is disappointing and difficult. Apart from conventional therapy with system...

Bullous pemphigoid during ustekinumab therapy

BP: Bullous pemphigoid TNF-a: tumor necrosis factor-alfa INTRODUCTION Ustekinumab, a monoclonal antibody that blocks interleukin-12 and interleukin-23, is a biological therapy used to treat moderate-to-severe psoriasis. Bullous pemphigoid (BP) induced by antietumor necrosis factor-alfa (TNF-a) agents has been described in the literature. No cases have been reported with ustekinumab. We report a...

Development of bullous pemphigoid during nivolumab therapy

Bregs: B regulatory cells BP: bullous pemphigoid CTLA-4: cytotoxic T-lymphocyteeassociated protein 4 IRAE: immune-related adverse events PD-1: programmed cell death protein 1 PD-L1: programmed death ligand

A new approach on bullous pemphigoid therapy.

Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering skin disease seen in the elderly. The prognosis of BP is poor, since the 1-year mortality rate has been reported to range from 25% to 40% in recent studies [1]. Corticosteroids have been so far the mainstay of therapy [2]. Antibiotics and immunosuppressants, such as cyclophosphamide and azathioprine, have also been us...

Bullous pemphigoid